Table 5.
Primary endpoint meta-analysis
| Endpoint |
Closure Trial |
PC Trial |
Respect Trial |
Random Effects Model |
|||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | HR | 95%CI | HR | 95%CI | HR | 95% CI | p-value | |
|
ITT Population | |||||||||
| Composite endpoint of all devices |
0.78 |
0.45,1.35 |
0.63 |
0.24,1.62 |
0.49 |
0.22,1.11 |
0.66 |
0.43,1.01 |
0.06 |
| Composite endpoint of Amplatzer device |
|
|
0.63 |
0.24,1.62 |
0.49 |
0.22,1.11 |
0.54 |
0.29,1.01 |
0.05 |
|
Per Protocol | |||||||||
| Composite endpoint of all devices |
0.74 |
0.42,1.29 |
0.70 |
0.27,1.85 |
0.37 |
0.14,0.96 |
0.64 |
0.41,0.98 |
0.04 |
| Composite endpoint of Amplatzer device | 0.70 | 0.27,1.85 | 0.37 | 0.14,0.96 | 0.64 | 0.44,0.97 | 0.03 | ||